PRNewsWire
25 Jun 2026, 08:52 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The lawsuit claims Immutep knew the TACTI-004 trial would fail to meet primary efficacy endpoints while publicly claiming 'strong operational progress'. — The failure of a primary clinical endpoint for a lead drug candidate is a fundamental blow to a biotech company's valuation.
-0.80Immutep Limited is facing a class action lawsuit alleging it made false and misleading statements regarding the TACTI-004 trial of eftilagimod alfa. — Allegations of securities fraud and misleading claims about clinical trial progress typically trigger investor sell-offs and increase legal risk.
-0.60Which stocks this story touches
The company is being sued for securities law violations.
Continue reading
6 related stories
Search tags
The company is facing a class action lawsuit alleging false and misleading statements regarding clinical trial results.
The company is being sued for securities law violations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
